Journal profile · Medicine-Oncology
Journal of Immunotherapy and Precision Oncology
ISSN 2666-2345 · eISSN 2590-017X · Innovative Healthcare Institute · United States
Journal of Immunotherapy and Precision Oncology: CAS Zone 4 · Medicine (2026 Xinrui edition); fully open access; APC about USD 2,400; median 112 days to acceptance (42 articles, last 24 months); 30 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Journal of Immunotherapy and Precision Oncology is published by Innovative Healthcare Institute and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research and Cancer Genomics and Diagnostics, together about 38.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Medicine-Oncology
Editor-in-chief Aung NaingPublisher website
Editorial board by country: none in mainland China; most named United States 13, Canada 2, Hong Kong, China 1, Taiwan, China 1, United Kingdom 1 (22 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine22.8%
- CAR-T cell therapy researchMedicine8.1%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7.9%
- Lung Cancer Treatments and MutationsMedicine6.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.5%
- Colorectal Cancer Treatments and StudiesMedicine5%
- Lung Cancer Diagnosis and TreatmentMedicine3.7%
- PARP inhibition in cancer therapyMedicine3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 5.1LetPub ·
- SJR 2026-06
- 1.37LetPub ·
- SNIP 2026-06
- 0.95LetPub ·
- h-index
- 20OpenAlex ·
- i10-index
- 46OpenAlex ·
- 2-year mean citedness
- 3.04OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 96.39%LetPub ·
Volume
- Articles per year
- 29LetPub ·
Articles by year OpenAlex count · 252 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 19 | 19 | 4 |
| 2025 | 30 | 30 | 80 |
| 2024 | 32 | 32 | 162 |
| 2023 | 31 | 31 | 303 |
| 2022 | 24 | 24 | 337 |
| 2021 | 34 | 34 | 302 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
112 daysMedian, submission to acceptance · P25–P75 68 days – 144 days
- Acceptance to online
- median 58 days (42 articles)
- Submission to online
- median 173 days
- Sample
- 42 articles with submission and acceptance dates (64 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 24 weeksLetPub ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,400 | Yes | CC BY, CC BY-NC-ND, Public domain | |
| OpenAlex | USD 2,400 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Innovative Healthcare Institute
- Country or region
- United States
- Language
- English
- ISSN
- 2666-2345
- Electronic ISSN
- 2590-017X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Immunotherapy and Precision Oncology
What CAS zone is Journal of Immunotherapy and Precision Oncology in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Journal of Immunotherapy and Precision Oncology?
Based on the dates recorded on 42 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 112 days (interquartile range 68–144 days); authors report an average review time of about 24 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Immunotherapy and Precision Oncology based?
Of the 22 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (13), Canada (2) and Hong Kong, China (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Immunotherapy and Precision Oncology?
According to LetPub and DOAJ records, Journal of Immunotherapy and Precision Oncology is indexed in ESCI, Scopus and DOAJ.
Is Journal of Immunotherapy and Precision Oncology open access, and what is the APC?
Journal of Immunotherapy and Precision Oncology is a fully open-access journal. APC about USD 2,400.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .